French pharmaceutical giant Sanofi (SNY -2.27%) is currently the leader in the long-acting insulin space. Its product Lantus is used by diabetes patients around the world, and it's currently the company's best selling drug. However, what are the challenges up ahead for Sanofi? Will Lantus' multibillion-dollar sales continue in perpetuity? What about Sanofi's other insulin drug Apidra -- is this product a weakness in the company's diabetes franchise?
In the following video, health care analyst Max Macaluso discusses these topics and probes Sanofi's strengths and weaknesses.
